Cargando…

Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience

SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third most common cause of cancer-related mortality worldwide. Transarterial chemoembolization has shown survival benefits in patients with early to intermediate-stage HCC, becoming the standard of care and re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdelrahim, Maen, Victor, David, Esmail, Abdullah, Kodali, Sudha, Graviss, Edward A., Nguyen, Duc T., Moore, Linda W., Saharia, Ashish, McMillan, Robert, Fong, Joy N., Uosef, Ahmed, Elshawwaf, Mahmoud, Heyne, Kirk, Ghobrial, Rafik M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Viewpoint
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833802/ https://www.ncbi.nlm.nih.gov/pubmed/35158918 http://dx.doi.org/10.3390/cancers14030650

Ejemplares similares

Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study
por: Ren, Baosheng, et al.
Publicado: (2019)

Transarterial chemoembolization (TACE) plus sorafenib: a real winning combination?
por: Adhoute, Xavier, et al.
Publicado: (2020)

Transarterial Chemoembolization (TACE) plus Sorafenib Versus TACE for Intermediate or Advanced Stage Hepatocellular Carcinoma: A Meta-Analysis
por: Zhang, Leida, et al.
Publicado: (2014)

Diffuse Recurrence of Hepatocellular Carcinoma After Liver Resection: Transarterial Chemoembolization (TACE) Combined With Sorafenib Versus TACE Monotherapy
por: Yao, Wang, et al.
Publicado: (2020)

Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)
por: Wiggermann, Philipp, et al.
Publicado: (2011)

Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study
por: Qiu, Zhiyu, et al.
Publicado: (2021)

Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis
por: Zhang, XiuPing, et al.
Publicado: (2017)

Identifying optimal candidates of transarterial chemoembolization (TACE) vs. sorafenib in patients with unresectable hepatocellular carcinoma
por: Zhao, Shoujie, et al.
Publicado: (2020)

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
por: Kudo, Masatoshi, et al.
Publicado: (2020)

Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients
por: Zhu, Dedong, et al.
Publicado: (2019)

Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib versus DEB-TACE alone in treating huge hepatocellular carcinoma patients
por: Li, Ningjie, et al.
Publicado: (2022)

Transcatheter arterial chemoembolization (TACE) combined with γ-knife compared to TACE or γ-knife alone for hepatocellular carcinoma
por: Cai, Yeyu, et al.
Publicado: (2018)

Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety
por: Li, Hui, et al.
Publicado: (2019)

A review of applying transarterial chemoembolization (TACE) method for management of hepatocellular carcinoma
por: Ghanaati, Hossein, et al.
Publicado: (2021)

Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis
por: Duan, Ruihua, et al.
Publicado: (2023)

A retrospective study of transarterial chemoembolization (TACE) combined with lenvatinib compared with TACE monotherapy for BCLC B2 stage hepatocellular carcinoma
por: Liu, Junning, et al.
Publicado: (2023)

Systematic Review and Meta-analysis of Endostar Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone for Hepatocellular Carcinoma
por: Zhang, Ya-Qing, et al.
Publicado: (2017)

Single medium-sized hepatocellular carcinoma treated with sequential conventional transarterial chemoembolization (cTACE) and microwave ablation at 4 weeks versus cTACE alone: a propensity score
por: Zhu, Zi-yi, et al.
Publicado: (2022)

Initial Transarterial Chemoembolization (TACE) Using HepaSpheres 20–40 µm and Subsequent Lipiodol TACE in Patients with Hepatocellular Carcinoma > 5 cm
por: Cho, Su Min, et al.
Publicado: (2021)

Outcome of conventional transarterial chemoembolization (cTACE) in the management of spontaneously ruptured hepatocellular carcinoma
por: Patidar, Yashwant, et al.
Publicado: (2019)

Sarcopenia indicate poor survival in patients undergoing transarterial chemoembolization (TACE) for hepatic malignancies
por: Loosen, Sven H., et al.
Publicado: (2023)

A Comparison of Adverse Events Among Radiofrequency Ablation, Conventional Transarterial Chemoembolization (TACE) and Drug-Eluting Bead TACE in Treating Hepatocellular Carcinoma Patients
por: Cao, Guangshao, et al.
Publicado: (2021)

Drug-eluting microspheres transarterial chemoembolization (DEM TACE) in patients with liver metastases. Pilot study
por: Jarząbek, Magdalena, et al.
Publicado: (2011)

Sarcopenia Is a Negative Prognostic Factor in Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatic Malignancies
por: Loosen, Sven H., et al.
Publicado: (2019)

Efficacy and safety of apatinib combined with transarterial chemoembolization (TACE) in treating patients with recurrent hepatocellular carcinoma
por: Gu, Huiying, et al.
Publicado: (2020)

A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE
por: Xia, Zicong, et al.
Publicado: (2022)

Evaluation of the Safety and Efficacy of Conventional Transarterial Chemoembolization (cTACE) and Drug-Eluting Bead (DEB)-TACE in the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review
por: Ayyub, Javaria, et al.
Publicado: (2023)

Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: An Institution Experience
por: Abdelrahim, Maen, et al.
Publicado: (2022)

The Prognostic Value of (18)F-FDG PET/CT for Hepatocellular Carcinoma Treated with Transarterial Chemoembolization (TACE)
por: Ma, Wenhui, et al.
Publicado: (2014)

Safety and efficacy of transarterial chemoembolization with degradable starch microspheres (DSM-TACE) in the treatment of secondary liver malignancies
por: Schicho, Andreas, et al.
Publicado: (2018)

Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
por: Kim, David Sooik, et al.
Publicado: (2021)

Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study
por: Yuan, Jia, et al.
Publicado: (2019)

Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression
por: Zou, Xinhua, et al.
Publicado: (2021)

TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial
por: Féray, Cyrille, et al.
Publicado: (2023)

Transplant Oncology: An Evolving Field in Cancer Care
por: Abdelrahim, Maen, et al.
Publicado: (2021)

The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE
por: Kimura, Yusuke, et al.
Publicado: (2020)

Changing TACTICS in intermediate HCC: TACE plus sorafenib
por: Radu, Pompilia, et al.
Publicado: (2020)

Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study
por: Gruber-Rouh, Tatjana, et al.
Publicado: (2018)

Rate and Predictive Factors for Sustained Complete Response after Selective Transarterial Chemoembolization (TACE) in Patients with Hepatocellular Carcinoma
por: Bannangkoon, Kittipitch, et al.
Publicado: (2018)

Alpha-Fetoprotein Response after First Transarterial Chemoembolization (TACE) and Complete Pathologic Response in Patients with Hepatocellular Cancer
por: Masior, Łukasz, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uf35kqjdt44fg4jvrpop3dsict